300 related articles for article (PubMed ID: 18534276)
1. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
[TBL] [Abstract][Full Text] [Related]
2. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
5. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
6. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
7. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
8. Istaroxime: a new luso-inotropic agent for heart failure.
Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
[TBL] [Abstract][Full Text] [Related]
9. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
[TBL] [Abstract][Full Text] [Related]
10. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Wehrens XH
Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
[TBL] [Abstract][Full Text] [Related]
11. Istaroxime in heart failure new hope or more hype.
Dec GW
J Am Coll Cardiol; 2008 Jun; 51(23):2286-8. PubMed ID: 18534277
[No Abstract] [Full Text] [Related]
12. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
[TBL] [Abstract][Full Text] [Related]
13. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
Carubelli V; Zhang Y; Metra M; Lombardi C; Felker GM; Filippatos G; O'Connor CM; Teerlink JR; Simmons P; Segal R; Malfatto G; La Rovere MT; Li D; Han X; Yuan Z; Yao Y; Li B; Lau LF; Bianchi G; Zhang J;
Eur J Heart Fail; 2020 Sep; 22(9):1684-1693. PubMed ID: 31975496
[TBL] [Abstract][Full Text] [Related]
14. Effects of a novel inotropic agent (OPC-18790) on systolic and diastolic function in patients with severe heart failure.
Hoit BD; Burwig S; Eppert D; Bhat G; Walsh RA
Am Heart J; 1994 Dec; 128(6 Pt 1):1156-63. PubMed ID: 7985596
[TBL] [Abstract][Full Text] [Related]
15. SERCA2a Agonist Effects on Cardiac Performance During Exercise in Heart Failure With Preserved Ejection Fraction.
Sarma S; MacNamara JP; Hieda M; Howden EJ; Lawley JS; Livingston S; Samels M; Levine BD
JACC Heart Fail; 2023 Jul; 11(7):760-771. PubMed ID: 37086245
[TBL] [Abstract][Full Text] [Related]
16. Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis.
MacGowan GA; Haber HL; Cowart TD; Tedesco C; Wu C; Feldman MD
J Am Coll Cardiol; 1998 May; 31(6):1344-51. PubMed ID: 9581731
[TBL] [Abstract][Full Text] [Related]
17. Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.
Arici M; Ferrandi M; Barassi P; Hsu SC; Torre E; Luraghi A; Ronchi C; Chang GJ; Peri F; Ferrari P; Bianchi G; Rocchetti M; Zaza A
J Pharmacol Exp Ther; 2023 Jan; 384(1):231-244. PubMed ID: 36153005
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Metra M; Chioncel O; Cotter G; Davison B; Filippatos G; Mebazaa A; Novosadova M; Ponikowski P; Simmons P; Soffer J; Simonson S
Eur J Heart Fail; 2022 Oct; 24(10):1967-1977. PubMed ID: 35867804
[TBL] [Abstract][Full Text] [Related]
19. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
[TBL] [Abstract][Full Text] [Related]
20. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV
Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
